On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

420 with CNW — Colorado Firm Set to Conduct Marijuana Research for Alzheimer’s Patients

Over the past decade or so, plenty of studies have found marijuana to be effective at treating the symptoms of a variety of medical conditions. However, most of this research is in its infancy, and experts unanimously agree that we need a lot more clinical trials to definitively prove marijuana’s medical potential.

In Colorado, MedPharma Research, a leading research company in the medical cannabis field, recently announced that it had been granted funding to research the efficacy of marijuana in Alzheimer’s patients. The company submitted a proposal to the Colorado State University Institute of Cannabis Research’s (ICR) FY23 Cannabis Research Opportunity and was ultimately selected for funding.

A panel from the ICR reviewed MedPharma’s proposal and scored it based on approach, significance, environment, broader impact and data analysis. Titled “Isolation and Pharmacological Evaluation of Phytocannabinoids for Alzheimer’s Disease,” the proposal received praise from the ICR panelists due to its novelty, type of training scientific interns received, and the clarity with which it defined evaluation metrics for every data analysis goal.

Given that Alzheimer’s affects millions of Americans and still has no cure, plenty of people stand to benefit if the research from MedPharma uncovers concrete proof of marijuana’s effectiveness. As it stands, there are a variety of treatments that can be used to alleviate Alzheimer’s symptoms and change the progression of the disease. However, there is no cure for the neurodegenerative disease.

The condition is associated with increased levels of inflammation and oxidative stress in the brain. Cannabidiol (CBD), which has anti-inflammatory and anti-oxidant properties, could be used to treat Alzheimer’s by addressing the inflammatory and oxidative mechanisms behind the disease. Scott Karolchyk, MS, RPh, MedPharma director of formulation and development, notes that CBD also has neuroprotective properties, has proven to be effective in vivo in previous studies, and is nonpsychoactive, making it an even more suitable candidate for research into treatments for Alzheimer’s.

He states that the study will give MedPharma the data it needs to develop innovative, bioavailable and bioequivalent dosage forms. MedPharma President Albert Gutierrez said that undertaking such an unprecedented study is what sets his company apart from other companies in the marijuana research and development game. MedPharma will pursue any means it can to develop therapies to treat Alzheimer’s, he said, and studying how compounds such as CBD function will bring the company one step closer to understanding Alzheimer’s.

MedPharma Director of Pharmacology & Experimental Therapeutics Duncan Mackie, PhD, called the announcement a big win for the cannabinoid research community as a whole, stating that it will offer the first clear cellular and mechanistic evidence on the efficacy of cannabis and cannabinoid products against Alzheimer’s.

This and other ongoing marijuana studies are likely to be followed closely by the cannabis industry and its established actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS) since they will add onto the scientific documentation debunking the thinking at the DEA that marijuana has no medical value and should therefore remain a highly controlled substance.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Archives

Select A Month

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722